Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).
Ursula Matulonis
No relevant relationships to disclose
Gerburg M. Wulf
No relevant relationships to disclose
Michael J. Birrer
No relevant relationships to disclose
Shannon Neville Westin
No relevant relationships to disclose
Philippa Quy
No relevant relationships to disclose
Katherine M. Bell-McGuinn
No relevant relationships to disclose
Brian Lasonde
No relevant relationships to disclose
Christin Whalen
No relevant relationships to disclose
Carol Aghajanian
No relevant relationships to disclose
David B. Solit
No relevant relationships to disclose
Gordon B. Mills
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Lewis Cantley
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose